Peninsula startup ’s all-star lineup, fresh off $192M round, circles next-generation cell therapies

Touting a board that includes the former head of the National Cancer Institute, the ex-CEO of Novartis and a well-known Stanford University researcher, a young Peninsula company emerged with a $192 million round to attack cancer and other diseases with off-the-shelf cell therapies. Orca Bio — incubated at the nonprofit StartX accelerator program associated with Stanford — said Wednesday that its Series D funding was led by Lightspeed Venture Partners and an undisclosed investor. Founders Ivan…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news